supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months

August 2012

You'll see supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months.

It's not a drug shortage. Lepirudin is being discontinued by the manufacturer for business reasons...not safety concerns.

This leaves just one first-line agent for preventing and treating thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote